// App-Quantinova.ai

PO0560 : Pegunigalsidase Alfa, Novel Pegylated Enzyme Replacement Therapy, Evaluated in Fabry Patients with Progressing Kidney Disease: A Randomized Clinical Trial Study Design

Researchers

Presenter

  • Warnock DavidG

Principal Investigators

  • Hughes Derralynn

  • Alon Sari

  • Chertkoff Raul

  • Almon Einat

  • Schiffmann Raphael

Medical Centers

  • UAB Medicine Birmingham Alabama United States

  • LSDU Institute of Immunity and Transplantation Royal Free London NHS Foundation Trust London United Kingdom

  • Protalix Biotherapeutics Carmiel Northern Israel

  • Baylor Institute of Metabolic Diseases Baylor University Medical Center Dallas Texas United States

Locations

  • United States

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Renal disease

  • Fabry disease

Biomarkers

  • N/A

Drug/Treatment

  • Agalsidase beta

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Active Comparator

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved